Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
59,112,975
-
Total 13F shares
-
32,250,659
-
Share change
-
+913,316
-
Total reported value
-
$828,539,736
-
Price per share
-
$25.75
-
Number of holders
-
70
-
Value change
-
-$17,650,444
-
Number of buys
-
38
-
Number of sells
-
36
Institutional Holders of Cullinan Therapeutics, Inc. - Common Stock (CGEM) as of Q2 2021
As of 30 Jun 2021,
Cullinan Therapeutics, Inc. - Common Stock (CGEM) was held by
70 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
32,250,659 shares.
The largest 10 holders included
MPM Oncology Impact Management LP, Foresite Capital Management V, LLC, CHI Advisors LLC, FMR LLC, BAUPOST GROUP LLC/MA, EVENTIDE ASSET MANAGEMENT, LLC, AMERICAN INTERNATIONAL GROUP, INC., VANGUARD GROUP INC, ORBIMED ADVISORS LLC, and Rock Springs Capital Management LP.
This page lists
70
institutional shareholders reporting positions in this security
for the Q2 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.